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Abstract
Background: Pulmonary arterial hypertension (PAH) is a rare, progressive, fatal vascular disorder. Genetic
predisposition plays vital roles in the development of PAH, with most mutations being identified in genes involved
in the transforming growth factor beta (TGF-β) signaling pathways. Defects in the BMP9 gene have been
documented in hereditary hemorrhagic telangiectasia (HHT), the most common inherited vascular disorder, which
is occasionally associated with PAH. Selective enhancement of endothelial BMPR2 with BMP9 reverses pulmonary
arterial hypertension.
Case presentation: We report the case of a 5-year-old Hispanic boy who was diagnosed with severe PAH and
right heart failure at 3 years of age. During his stay in the pediatric intensive care unit, treatment was initiated with
inhaled nitric oxide and intravenous epoprostenol; he subsequently was transitioned to treprostinil, sildenafil, and
prophylactic enoxaparin. Now, two years later, the child is asymptomatic on sildenafil, bosentan, subcutaneous
treprostinil, and warfarin. Genetic screening revealed a novel homozygous nonsense mutation in the BMP9 gene
(c.76C > T; p.Gln26Ter). The child had no telangiectasias or arteriovenous malformations; family history also was
negative. Subsequent parental testing showed both parents were heterozygous for the same mutation, indicating
that the child inherited the BMP9 mutant allele from each parent.
Conclusion: To our knowledge, this is the first report of a BMP9 mutation in a patient with PAH. The homozygous
nonsense mutation may account for the early onset and severity of PAH in this patient and also fit the ‘two-hit’
model we proposed previously. The absence of clinical symptoms for PAH in the parents may be due to
incomplete penetrance or various expressivities of the BMP9 mutations. Our study expands the spectrum of
phenotypes related to BMP9 mutations.
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Background
Pulmonary arterial hypertension (PAH) is a progressive
disease characterized by elevated mean pulmonary artery
pressure (mPAP) of 25 mm Hg or more and pulmonary
capillary wedge pressure (PCWP) of 15 mm Hg or less. In
the current guideline, pulmonary vascular resistance
(PVR) greater than 3 wood units was added as part of the
hemodynamic definition of PAH [1]. The etiology of PAH
is heterogeneous and incompletely understood. Gene mu-
tations that have been described as promoters of PAH in-
clude mutations in the gene coding BMPR2 (bone
morphogenetic protein receptor type II), a member of the
transforming growth factor beta (TGF-β) signaling path-
way, which has been identified in approximately 70 % of
familial and up to 25 % of sporadic cases [2]. Other TGF-
β signaling pathway partners, such as ACVRL1 (ALK1:ac-
tivin receptor-like kinase type 1), ENG (endoglin),
SMAD8, and SMAD4, are also reported to be involved in
the pathogenesis of PAH [3]. Besides, potassium channel
genes KCNA5 and KCNK3, NOTCH1, NOTCH3,
TOPBP1 and EIF2AK4 (eukaryotic translation initiation
factor 2) were documented as PAH disease causing genes
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[3–5]. BMP9/GDF2 may also be responsible for PAH by
specifically activating the ALK1/BMPR2/ENG pathway
and stimulating ET-1 (endothelin 1) via several SMAD
pathways [6]. This present study is the first to identify a
homozygous nonsense mutation in BMP9 in a patient
with PAH and expands the spectrum of phenotypes re-
lated to BMP9 mutations.
Case presentation
The proband, a 5-year-old boy, and his family members
were enrolled in the study after informed written con-
sent was obtained and this study was approved by the
institutional review board. This former full-term child
presented at 3 years of age with worsening dyspnea and
exercise intolerance. He was noted to have perioral
cyanosis, a new murmur, and cardiomegaly on chest X-
ray. Echocardiogram showed a severely dilated main
pulmonary artery and branch pulmonary arteries and
dilated right atrium and right ventricle without any evi-
dence of congenital heart disease. The predicted right
ventricular systolic pressure was ~104 mmHg + right
atrial pressure (simultaneous systemic blood pressure
102/78 mmHg), and the predicted pulmonary artery
end-diastolic pressure was ~44 mmHg + RVEDP (right
ventricular end-diastolic pressure). Brain-type natri-
uretic peptide (BNP) at admission was 4241 pg/mL
(reference range, 0–100 pg/mL). He was diagnosed with
PAH and started on subcutaneous infusion of 2 ng/kg/
min of epoprostenol that was titrated upwards to a goal
of 40 ng/kg/min, then transitioned to treprostinil of
80 ng/kg/min. During the admission, he was also
started on sildenafil (1 mg/kg/dose) and prophylactic
enoxaparin. Echocardiogram at discharge showed a
right ventricular systolic pressure of ~59 mmHg (sys-
temic blood pressure 90/50 mmHg). The right ventricle
remained severely dilated with qualitatively moderate
to severely depressed right ventricular systolic function.
No pericardial effusion was noted. BNP was 650 pg/mL.
Cardiac catheterization was done three months later on
dual therapy and showed mild-moderate PH (Table 1).
The cardiac catheterization data revealed that at rest, he
had normal saturations and therefore there was no
evidence of shunting or a mixing lesion. The blood was
also oxygenated appropriately as it passed through the
lungs. Mean artery pressures were elevated (>25 mmHg),
capillary wedge pressure was normal (< 15 mmHg) and
vascular resistance was elevated (> 2 WU/m2), consistent
with diagnosis of PAH.
Two years after his initial diagnosis, the child was doing
well and was New York Heart Association functional class
I. He is maintained on sildenafil (20 mg three times daily),
bosentan (62.5 mg twice daily), treprostinil (121 ng/kg/min
subcutaneously), and warfarin (3 mg daily). Echocardio-
gram showed trace tricuspid and pulmonary regurgitation
and a mildly dilated main pulmonary artery. The right
ventricle was moderately dilated with normal function. The
family history is otherwise negative. No signs or symptoms
of PAH or hereditary hemorrhagic telangiectasia (HHT)
showed in either parent. They are from the same town in
Mexico and denied any known consanguinity. Grandpar-
ents did not have HHT, nor did they have prolonged bleed-
ing or PAH. Paternal grandmother was alive at time of case
report; remaining grandparents were already deceased.
For genetic analysis, DNA extraction, polymerase chain
reaction (PCR) and sequence analysis were performed
according to our protocols [7]. Genomic primer pairs were
designed to amplify all of the coding regions and the
intron-exon boundaries of known PAH-associated
genes including BMPR2 [NM_001204.6], ACVRL1
[NM_001077401.1], ENG [NM_001114753.2], SMAD8
[NM_005905.5], SMAD4 [NM_005359.5], CAV1 [NM_001
753.4], BMP9/GDF2 [NM_0016204.1], KCNK3 [NM_0
02246.2], KCNA5 [NM_002234.3], EIF2AK4 [NM_001013
703.3], TOPBP1 [NM_007027.3], NOTCH1 [NM_01761
7.3], and NOTCH3 [NM_000435.2]. We identified a homo-
zygous nonsense mutation (c.76C >T) of the BMP9/GDF2
gene (Fig. 1). This is a novel mutation that causes change
from glutamine to terminator at amino acid position 26
(p.Gln26Ter). The parents are both heterozygotes for
the same mutation, indicating that the child inherited
a copy from each parent. Besides the mutation, we
Table 1 Cardiac catheterization data
Saturations (%)
RA RPA LFA Sys
REST 80 81 100
On O2 (80 %) 91 100 %
On NO 89 100
Pressures (mm Hg)
RA RV RPA RPCW LFA
REST 6/6/6 38/2/7 42/20/30 7/7/7 88/46/61
Isoproterenol 2mcg 60/25/43 9/9/8 101/45/64
On O2 (80 %) 6/5/5 42/20/29 7/7/7 89/42/60
On NO 7/6/6 43/18/29 7/7/7 85/41
Thermodilution




Using the above values including an assumed VO2 of 155 ml/min/m2 and Hgb
11.4 g/dL, calculations were the following: Qp = 5.2 L/min/m2, Qs = 5.2 L/min/
m2; Qp:Qs = 1:1, PVR 4.4 WU/m2. No significant changes noted in pressures
while on O2, NO or during administration of isoproterenol
Abbreviations: RPA right pulmonary artery, LFA left femoral artery, S/D/M
systolic, diastolic, mean artery pressures, RA right atrium, RV right ventricle,
RPCW right pulmonary capillary wedge, CO cardiac output, CI cardiac index, Qp
pulmonary blood flow, Qs systemic blood flow, PVR pulmonary
vascular resistance
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also found a number of polymorphisms (Additional
file 1: Table S1).
Conclusions
Various factors have been documented in the patho-
genesis of PAH, and genetic mutations of genes in-
volved in the TGF-β signaling pathway play essential
roles in it. Herein we report a novel homozygous
nonsense mutation in BMP9, another member of the
TGF-β signaling pathway, in a patient with PAH.
As a member of the bone morphogenetic proteins
(BMPs), BMP9 has been identified to be actively in-
volved in the TGF-β signaling pathway by specifically
binding to ALK-1, BMPR2, and ENG, which are caus-
ally related to PAH and HHT. The endothelial ALK1/
BMPR2 pathway is constitutively activated by circulat-
ing BMP9, and BMP9 induces BMPR2 expression in
endothelial cells in an ALK1-dependent manner [8]. In
HHT pathogenesis, missense mutations within the orphan
domain of ENG disrupt the high affinity interaction
between ENG and BMP-9 [9]. BMP9-specific mutations
were identified in patients with HHT [10], which is associ-
ated with a precapillary pattern of pulmonary hyperten-
sion that is histologically indistinguishable from idiopathic
PAH. Moreover, a recent study showed that selective
enhancement of endothelial BMPR2 with BMP9 reverses
PAH [11]. These data clearly indicate that the BMP-9/
ALK-1/BMPR2/ENG pathway is critical in the vascular
pathogenesis of PAH/HHT. Disruption of BMP9/ALK-1/
BMPR2/ENG pathway may, therefore, be important in the
development of PAH/HHT-related vascular changes. Also,
various studies have shown that BMP9 stimulates release
of ET-1 in vascular endothelial cells via several SMAD
pathways to regulate endothelial cell migration and angio-
genesis [12].
In our patient, the homozygous nonsense mutation re-
sulted in a premature truncation (c.76C > T, p.Gln26Ter).
This truncated BMP9 may cause abnormal remodeling of
pulmonary arterioles, which resulted in PAH due to the
loss of function of BMP9. Loss of function of BMP9 may
reduce the expression of BMPR2 and ALK-1 and disrupt
its interaction with ENG, both of which may contribute to
PAH pathogenesis. The homozygous nonsense mutation
may account for the early onset and severity of PAH in
this patient and also fit the ‘two-hit’ model we proposed
[7]. The absence of clinical symptoms in the parents may
be due to incomplete penetrance or various expressivities
of the BMP9 mutations. We believe that our study has
expanded the spectrum of phenotypes related to BMP9
mutations.
Fig. 1 Genetic screening of the PAH-causing genes in the index patient and the parent. Panel (a) shows normal nucleotide fragment of BMP9
with corresponding amino acids underneath. Panel (b) identifies the homozygous nonsense mutation at nucleotide position 76 (c.76C > T) in the
exon 1 of the BMP9 gene (NM_0016204.1), which causes the amino acid change from glutamine to tryptophan at peptide position of 26
(p.Gln26Ter) in the index patient. Panel (c) shows the heterozygous nonsense mutation at nucleotide position 76 (c.76C > T) in the exon 1 of the
BMP9 gene (NM_0016204.1) found in the parent
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Consent
Written informed consent was obtained from the patient
and his parents for publication of this case report. A
copy of the written consent is available for review by the
Editor of this journal.
Additional file
Additional file 1: Table S1. DNA alterations identified in the 13 PAH-
associated genes. (DOC 40 kb)
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